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Recent studies found that high glucose increases the expression of tumor suppressor factor p53. And in the process 
of diabetic kidney disease (DKD) development p53 involves in regulating multiple signaling pathways. In addition, 
microRNAs (miRNAs) involve in many diseases pathogenesis. And miRNAs affect DKD development via adjusting 
multiple mechanisms. More importantly, p53/miRNAs signaling may participate in a variety of signaling pathways 
regulating kidney inflammation and fibrosis to control DKD pathological development. However, the mechanism 
of p53/miRNAs signaling participating in DKD pathological development is not yet clear. To illuminate the role of 
p53/miRNAs signaling may inspire a new thinking for elucidating the pathological mechanism of DKD, and 
provide a new theoretical basis for the prevention and treatment of DKD. 
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Currently, with the improvement of people’s living 
standard and the changes in life style, the incidence of type 2 
diabetes mellitus (T2DM) increased year by year. Diabetic 
kidney disease (DKD) is one of the most main microvascular 
complications of T2DM. And it is also one of the main reasons 
leading to end stage renal disease. More importantly, statistics 
data have shown that 20%-40% of people in patients with 
diabetes can develop DKD [1]. Consequently, early diagnosis 
and treatment of DKD could reduce or delay the onset of 
diabetic kidney damage, and improve the quality of patient’s 
life. It will provide important clinical significance. 
 
Recent study found that high glucose raises the expression 
of p53 in kidney. Inhibiting p53 expression attenuates high 
 
glucose-induced acute kidney injury [2]. Besides, p53 and 
microRNAs (miRNAs) may regulate transforming growth 
factor-β1 (TGF-β1) expression in diabetes mice to affect the 
development of diabetes renal fibrosis [3]. However, the role of 
p53 regulating miRNAs in DKD pathological mechanism is 
not yet clear. To clear the role of p53/miRNAs signaling in 
DKD mechanism may help to provide new train of thought for 
elucidating the pathological mechanism of DKD. In this paper 
we will review the role of p53/miRNAs signaling in DKD. 
 
The function of p53 
 
Transcription factor p53 plays an important role in the 
process of inhibiting tumor. It inhibits tumor formation by 
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Figure 1. p53/miRNAs signaling related to diabetes development. HG: high glucose; Akt: 
serine/threonine kinase; AMPK: activating adenosine monophosphate activated protein kinase; SIRT1: sirtuin 
1; FoxOs: forkhead box O; ROS: reactive oxygen species. 
 
means of promoting DNA repair, preventing cell cycling, 
inducing cell aging and apoptosis [4, 5]. Sirtuin 1 (SIRT1) 
weakens the effect of p53 inhibiting tumor via deacetylation 
[6]. p53 activated by SIRT1 inhibitor increases the activity of 
nuclear factor κB p65 (NF-κB p65). Furthermore, it promotes 
cell apoptosis and the expression of pro-inflammatory factor 
as well [7]. SIRT1 may also suppress the activity of forkhead 
box O (FoxO) family via down-regulating p53 expression. 
And then it reduces reactive oxygen species (ROS) expression 
and apoptosis related to oxidative stress [8]. Activating 
adenosine monophosphate activated protein kinase (AMPK) 
phosphorylation can activate SIRT1, while suppressing 
AMPK activity can increase p53 acetylation [9]. It suggests that 
increasing the activity of AMPK phosphorylation may activate 
SIRT1 and attenuate the acetylation of p53, which results in 
inhibiting the activity of NF-κB p65 and FoxO. Thereby, 
AMPK/SIRT1 signaling inhibits cell apoptosis and decreases 
the expression of pro-inflammation factor via down-regulating 
p53. 
 
Although p53 often acts as a protective factor in cancer, it 
is a pathogenic molecule in many non-cancer diseases. In islet 
β cell cytoplasm p53 induces mitochondria dysfunction and 
impaired insulin secretion. As a result, it promotes diabetes 
development [10]. Besides, high glucose increases p53 
expression via inhibiting AMPK/SIRT1 signaling pathways in 
liver cells, which causes lipid accumulation and insulin 
resistance [11]. Further study used metformin to activate high 
glucose-inhibited AMPK/SIRT1 signaling pathway. And 
results revealed that the expression of p53 protein significantly 
decreased. While over-expressed p53 reduces the expression 
of SIRT1 protein and inhibits metformin-activated AMPK 
signaling, accompanied by the decrease of triglycerides [12]. 
It suggests that there is a bidirectional interaction between 
 p53 and AMPK/SIRT1 signaling in the pathogenesis and 
treatment of diabetes. However, the specific mechanism of 
p53 in diabetes and its complications is not yet clear. 
 
The function of microRNAs 
 
As a kind of small non-encoded RNA in body, miRNAs can 
regulate target gene expression at the translation level, which 
depends on base pairing between the ‘seed’ area of miRNAs 
and the 3’ untranslated regions of target genes’ mRNAs [13]. 
Bioinformatics research found that miRNAs can adjust more 
than 60% gene expression in body [14]. miRNAs play an 
important role in cell growth, differentiation, apoptosis, and 
metabolism process. In addition, miRNAs are also involved in 
the pathogenesis of many diseases, such as oxidative stress, 
cardiovascular, cancer, and diabetes [15,16]. 
 
The expression of miR-200b, miR-429, and miR-200c 
increase significantly in diabetic vascular smooth muscle 
cells. And these miRNAs raise the expression of 
cyclooxygenase-2 (COX-2) and monocyte chemoattractant 
protein-1 (MCP-1), resulting in promoting inflammation [17]. 
miR-187 can decrease the expression of homeodomain- 
interacting protein kinase-3 (HIPK3), a factor regulating 
insulin secretion, and then reduce persistent hyperglycemia 
caused by glucose-stimulated insulin secretion [18]. Besides, 
high glucose promotes foxO3a expression via raising miR- 
30d expression, which raises the expression of inflammatory 
molecules and promotes cell apoptosis [19]. Research on 
diabetes patients also found that, with an increased level of 
urinary albumin, serum miR-130b level was significantly 
decreased and significantly negatively correlated with the 
serum levels of TGF-β1, hypoxia inducible factor 1α 
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Figure 2. p53/miRNAs signaling related to diabetic kidney disease development. GAS1: 
growth arrest-specific 1; SIRT1: sirtuin 1; AMPK: activating adenosine monophosphate 
activated protein kinase; Akt: serine/threonine kinase; HG: high glucose; ZEB1: zinc finger E- 
box binding homeobox 1; TGF-β1: transforming growth factor-β1; STAT3: transcription 3; 
mTOR: mammalian target of rapamycin. 
 
 (HIF-1α), and fibronectin (FN) [20]. It prompts that miRNAs 
may influence the development of diabetes via adjusting 
multiple signaling mechanisms. Furthermore, it may play a 
role in DKD pathogenesis. 
 
p53/microRNAs and diabetes 
 
Although more and more evidences suggests that miRNAs 
play a regulatory role in metabolic disease, the mechanism of 
p53 participating in the process of miRNAs regulating 
metabolism is not clear yet [18,19]. 
 
p53 can inhibit glycolysis by regulating miR-34, and then 
adjust the activity of a series of glycolytic enzymes such as 
hexokinase 1, hexokinase 2, and glucose 6 phosphate 
isomerase to enhance mitochondrial respiration [21]. 
Cristhianna et al. [22] found that miR-199a-5p level has certain 
connection with diabetes development. Serine/threonine 
kinase (Akt) reduces miR-199a-5p expression, accompanied 
by higher SIRT1 expression. And overexpression of miR- 
199a-5p can reverse the change of SIRT1 expression [23]. 
What’s more, studies found that p53 not only regulates the 
activity of Akt signaling pathways [24], also regulates 
AMPK/SIRT1 signaling pathways involved in the 
pathogenesis of diabetes mellitus [11,12]. It suggests that p53 
may participate in the process of miRNAs regulating diabetes 
pathogenesis.  It  is important to further explore the 
mechanism of p53/miRNAs in the development of diabetes 
and its complications. (Fig. 1) 
 
p53/microRNA and diabetic kidney disease 
 
The early change of diabetic kidney damage is glomerular 
hemodynamics change, including high filtration and high 
perfusion damage [25]. And the main pathological features of 
DKD are glomerular basement membrane thickening, 
extracellular matrix accumulation [26], and interstitial 
inflammation [27]. It promotes the process of kidney structure 
damage, such as glomerular sclerosis and interstitial fibrosis, 
which eventually leads to kidney failure. p53/miRNAs 
signaling may adjust a variety of signaling pathways to 
regulate DKD development. But the mechanism has not been 
fully elucidated. 
 
The role of p53/miR-34 signaling in DKD 
 
p53 regulates cell apoptosis via inhibiting miR-34 
expression [28]. Meanwhile, miR-34a can activate p53 to 
promote cell apoptosis by inhibiting SIRT1 expression [29]. In 
energy metabolism, p53 regulates miR-34 expression to 
inhibit glycolysis, and then enhances mitochondrial 
respiration [21]. Recent study has found that down-regulating 
miR-34 inhibits cell proliferation via inhibiting growth 
arrest-specific 1 (GAS1) in glomerular mesangial cells 
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cultured with high glucose. What’s more, down-regulating 
miR-34 can alleviate glomerular hypertrophy in diabetes mice 
[30]. It suggests that p53 may play a role in the process of 
diabetic kidney damage via regulating miR-34 expression. 
(Fig. 2) 
 
The role of p53/miR-192 signaling in DKD 
 
The expression of miR-192 increases in patients with early 
DKD [31]. Furthermore, specifically inhibiting renal miR-192 
expression alleviates renal fibrosis [32]. More importantly, 
study found that there is an interaction between p53 and miR- 
192, which regulates the downstream zinc finger E-box 
binding homeobox 1 (ZEB1) and TGF-β1 expression in 
diabetes mice renal. As a result, it affects the development of 
diabetic renal fibrosis [3]. It suggests that p53 may participate 
in the process of diabetic renal fibrosis through the mutual 
adjustment with miR-192, resulting in affecting the 
pathological development of DKD. (Fig. 2) 
 
The role of p53/miR-199a and AMPK/SIRT1 signaling in 
DKD 
 
High glucose raised p53 expression via inhibiting 
AMPK/SIRT1 signaling pathways [11]. Further evidence using 
metformin to activate AMPK/SIRT1 signaling can reduce p53 
expression, while over-expressed p53 reduces the expression 
of SIRT1 [12]. Activating the phosphorylation of AMPK 
suppresses insulin resistance [33]. It also alleviates the activity 
of high glucose-stimulated mammalian target of rapamycin 
(mTOR)/p70S6K signaling pathways in glomerular mesangial 
cells, and thereby inhibits the expression of cell proliferation 
and fibrosis [34]. 
 
Besides, high glucose increases miR-199a-5p expression in 
glomerular mesangial cells [35]. Meanwhile, Akt reduces miR- 
199a-5p expression and raises SIRT1 expression. And over- 
expressed miR-199a-5p revises the expression of SIRT1 [23]. 
The ectopic expression of p53 induces miR-199a-3p 
transcription, and then affecting the restructuring of mice 
embryonic fibroblast cells [36]. We speculate that p53 may 
regulate DKD development by AMPK/SIRT1 signaling 
pathways, in which process miR-199a may play a certain role. 
(Fig. 2) 
 
The role of p53/miR-21 and Akt/mTOR signaling in DKD 
 
miR-21 negatively regulates the expression of p53 [37]. And 
p53 also influents miR-21 expression via regulating signaling 
transduction and signal transducer and activator of 
transcription 3 (STAT3) [38]. miR-21 expression appears 
significant change in early DKD [39]. Besides, miR-21 
participates   in   diabetes   related   PI3K/Akt   signaling and 
mTOR signaling [40]. However, its function and mechanism is 
still controversial. Zhao H et al. [41] considered that miR-21 
regulates the activity of PI3K/Akt signaling to block 
glomerular stromal mast, which provides protection for early 
DKD [41]. Dey N et al. [41] considered that miR-21 may 
promote high glucose-induced mTOR expression and resulted 
in diabetic kidney damage. Research has found that activating 
p53 inhibits mTOR signaling [42]. Conversely, knocking out 
p53 gene significantly raises mTOR level and activates Akt 
protein [43]. More importantly, activating Akt/mTOR signaling 
increases DNA oxidative stress, and then promotes diabetic 
kidney damage [44]. It suggests that p53/miR-21 may 
participate in DKD development via regulating Akt/mTOR 
signaling. Further clarifying the mechanism is very important 
for clearing the pathogenesis of DKD. (Fig. 2) 
 
The role of p53/miRNAs and TGF-β/Smad signaling in 
DKD 
 
High glucose activates TGF-β/Smad signaling pathways to 
induce kidney ECM accumulating, which promotes interstitial 
fibrosis and glomerular mesangial expansion [25, 26]. There is a 
certain contact between miR-216, miR-217 and chronic 
kidney disease development. TGF-β up-regulates the 
expression of miR-216, 217 and activates Akt, resulting in 
contributing DKD development [45]. Kato M et al. [46] found 
that miR-192 could up-regulate these miRNAs expression. 
And p53 involved in the process of that miR-192 plays a role 
in the occurrence and development of DKD [3]. 
 
In addition, miR-224 not only plays a certain role in the 
development of diabetes, also plays a certain role in renal clear 
cell carcinoma [47]. More importantly, miR-224 participates in 
the process that TGF-β signaling pathways inhibits Smad4 
expression. And p53 could inhibit miR-224 expression by 
combining the promoter of miR-224 coding gene. Conversely, 
down-regulating miR-224 expression activates p53 and 
inhibits Smad4 expression [48]. Therefore, we speculate 
p53/miRNAs may regulate the activity of TGF-β/Smad 
signaling to affect DKD development. (Fig. 2) 
 
Based on the foregoing analysis, p53 and miRNAs has 
some correlation with DKD development. p53/miRNAs 
signaling may participate in a variety of signaling pathways 
regulating the pathological of DKD. However, the role of 
p53/miRNAs signaling in the pathological mechanism of 
DKD is not yet clear. To illuminate the role of p53/miRNAs 
signaling may inspire a new thinking for elucidating the 
pathological mechanism of DKD, and provide a new 
theoretical basis for the prevention and treatment of DKD. 
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